Lilly’s Mevidalen Misses Primary Endpoint in Alzheimer’s Trial

Share on Social Media

Eli Lilly's investigational dopamine D1 receptor modulator mevidalen failed the primary endpoint in the Phase 2 PRESENCE-ALZ Alzheimer's disease trial.

Eli Lilly’s mevidalen failed the primary endpoint in the Phase 2 PRESENCE-ALZ Alzheimer’s trial, with limited secondary efficacy signals and blood pressure increases.

Written By: Anshu Gupta, PharmD

Reviewed By: Pharmacally Editorial Team

Eli Lilly’s investigational drug mevidalen (LY3154207) failed to meet the primary efficacy endpoint in the Phase 2 PRESENCE-ALZ trial (NCT06538116), which evaluated its potential to improve cognition and daily functioning in people with mild-to-moderate Alzheimer’s disease (AD). The findings, presented at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference, provide clinical context for Lilly’s October 2026 decision to remove the Alzheimer’s program from its development pipeline.

PRESENCE-ALZ Evaluates Mevidalen in Alzheimer’s Disease

Conducted between August 2024 and May 2026, the randomized, double-blind, placebo-controlled study enrolled 304 adults across the United States and Japan. Participants were assigned in a 1:1:1 ratio to receive mevidalen 25 mg, mevidalen 50 mg, or placebo once daily for 24 weeks, followed by a two-week safety follow-up.

Eligible participants were aged 50–80 years, had evidence of Alzheimer’s disease pathology based on plasma phosphorylated tau 217 (p-tau217) testing or previous biomarker history, and experienced progressive cognitive decline affecting daily activities for at least six months. Baseline Mini-Mental State Examination (MMSE) scores ranged from 13 to 24.

Primary Efficacy Endpoint Not Achieved

The primary endpoint assessed change from baseline to Week 24 in the Integrated Alzheimer’s Disease Rating Scale (iADRS), a composite measure of cognitive performance and everyday functioning, with higher scores indicating better function.

The trial used a Bayesian analysis requiring a greater than 60% posterior probability that either mevidalen dose would provide at least a two-point improvement over placebo. Neither dose achieved this prespecified threshold:

  • Mevidalen 25 mg: 14.0% posterior probability; least-squares mean difference of 0.62 points versus placebo (95% CI, −2.27 to 3.50).
  • Mevidalen 50 mg: 21.2% posterior probability; least-squares mean difference of 0.95 points versus placebo (95% CI, −1.95 to 3.86).

Although numerical estimates were slightly higher with the 50 mg dose, neither treatment demonstrated the required cognitive and functional benefit.

Secondary Outcomes Show Limited Evidence of Improvement

Secondary and exploratory assessments evaluated cognition, daily functioning, global clinical status, neuropsychiatric symptoms, and daytime sleepiness. Outcome measures included the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog), verbal and category fluency tests, Digit Symbol Coding, MMSE, Alzheimer’s Disease Cooperative Study–Activities of Daily Living (ADCS-ADL), Epworth Sleepiness Scale (ESS), Quick Dementia Rating System (QDRS), and clinician-rated global assessments.

Among these measures, only the QDRS, a scale on which lower scores indicate less clinical impairment, demonstrated a nominally significant difference favouring mevidalen 50 mg over placebo. The reported treatment difference was approximately 1.04 points (nominal P = 0.025).

However, this isolated secondary signal was not accompanied by consistent improvements across other cognitive and functional endpoints. It therefore does not establish clinical efficacy following the failed primary endpoint.

Safety Findings and Blood Pressure Changes

Treatment-emergent adverse events (TEAEs) occurred at comparable frequencies across the three study arms: 65.7% with placebo, 65.1% with mevidalen 25 mg, and 62.5% with mevidalen 50 mg.

Serious adverse events were reported in 5.9%, 9.4%, and 5.2% of participants, respectively, with no deaths or major adverse cardiovascular events observed. The most frequently reported adverse events involved infections, laboratory abnormalities, and gastrointestinal disorders.

An important hemodynamic observation involved systolic blood pressure elevations during initial dosing. Participants receiving mevidalen experienced mean increases of approximately 8–11 mm Hg relative to pre-dose measurements during the four-hour post-dose monitoring period at titration visits. The protocol permitted permanent discontinuation of the assigned dose during initial titration if potentially clinically significant pre-dose or post-dose changes in blood pressure or pulse occurred.

D1 Receptor Modulation and Previous Clinical Findings

Mevidalen is an investigational dopamine D1 receptor (D1R) positive allosteric modulator designed to enhance receptor responses to endogenous dopamine. This approach was investigated as a potential strategy to improve cognitive function through enhanced dopaminergic signalling.

The compound was previously evaluated in the Phase 2 PRESENCE study in people with Lewy body dementia (LBD). That trial also missed its primary cognitive endpoint, although secondary signals were reported in global clinical impression, motor symptoms, and daytime sleepiness. The higher 75 mg dose was discontinued following four serious cardiovascular events, with persistent blood pressure increases also reported at that dose. These earlier cardiovascular observations provide additional context for interpreting the blood pressure findings in PRESENCE-ALZ.

Lilly Removes Mevidalen from Alzheimer’s Development Pipeline

Lilly removed mevidalen’s Alzheimer’s disease program from its clinical development pipeline in October 2026 following the Phase 2 program’s failure to meet the company’s internal criteria for success. The decision marks the discontinuation of mevidalen’s development for Alzheimer’s disease, following the absence of demonstrated clinical benefit in the PRESENCE-ALZ trial.

Clinical Interpretation

Lilly concluded that PRESENCE-ALZ did not provide evidence supporting significant clinical benefit from D1-mediated dopamine potentiation in people with mild-to-moderate Alzheimer’s disease. Neither tested dose achieved the prespecified iADRS benefit threshold. Although overall adverse event rates were comparable with placebo, the systolic blood pressure increases during titration remain relevant to the drug’s cardiovascular tolerability.

The isolated nominal improvement in QDRS requires cautious interpretation given the absence of corroborating improvements across other cognitive and functional measures. Although these findings do not rule out all potential therapeutic applications of D1 receptor modulation in neurodegenerative disorders, the tested mevidalen regimen failed to demonstrate the required efficacy in Alzheimer’s disease, prompting Lilly to discontinue the program.

References

Meglio M. Mevidalen Misses Primary Endpoint in Phase 2 Alzheimer Trial. Neurology Live. November 18, 2026.

Fleisher AS, Mehdiyoun NF, Hu H, Tronchin G, Hansson O. Safety and Efficacy of Mevidalen in Alzheimer’s Disease: A Phase 2, Randomized, Double-Blinded Trial. Presented at: Clinical Trials on Alzheimer’s Disease (CTAD) Conference; November 2026. Poster P-029.

Biglan K et al, Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial. Mov Disord. 2022 Mar;37(3):513-524. https://doi.org/10.1002/mds.28879

A Study of Mevidalen (LY3154207) in Participants with Alzheimer’s Disease, ClinicalTrials.gov ID NCT06538116

PharmD Intern

About the Writer

Anshu Gupta (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, regulatory affairs, and medical writing. She has presented research at academic conferences and completed certifications in Good Clinical Practice (GCP), ICH-GCP, and drug safety. Passionate about clinical trials and evidence-based medicine, she is committed to translating scientific evidence into accurate, reliable, and accessible healthcare content.


Share on Social Media
Scroll to Top